The Manufacturers Life Insurance Company Has $10.51 Million Stock Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

The Manufacturers Life Insurance Company decreased its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 30.8% during the 1st quarter, Holdings Channel reports. The institutional investor owned 348,898 shares of the company’s stock after selling 155,079 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Teva Pharmaceutical Industries were worth $10,509,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently modified their holdings of TEVA. Aster Capital Management DIFC Ltd bought a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter valued at about $25,000. Cornerstone Planning Group LLC increased its position in Teva Pharmaceutical Industries by 547.1% during the first quarter. Cornerstone Planning Group LLC now owns 893 shares of the company’s stock worth $27,000 after acquiring an additional 755 shares during the period. Allworth Financial LP increased its position in Teva Pharmaceutical Industries by 53.8% during the fourth quarter. Allworth Financial LP now owns 941 shares of the company’s stock worth $29,000 after acquiring an additional 329 shares during the period. EverSource Wealth Advisors LLC raised its stake in Teva Pharmaceutical Industries by 51.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock worth $32,000 after purchasing an additional 345 shares in the last quarter. Finally, Global Retirement Partners LLC raised its stake in Teva Pharmaceutical Industries by 27.3% in the 4th quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock worth $42,000 after purchasing an additional 292 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Eliyahu Sharon Kalif sold 153,251 shares of the company’s stock in a transaction on Thursday, May 14th. The stock was sold at an average price of $35.61, for a total transaction of $5,457,268.11. Following the completion of the sale, the executive vice president directly owned 172,184 shares in the company, valued at $6,131,472.24. This represents a 47.09% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Amir Weiss sold 10,679 shares of the firm’s stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $36.00, for a total value of $384,444.00. Following the completion of the sale, the chief accounting officer directly owned 20,016 shares in the company, valued at approximately $720,576. This represents a 34.79% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 270,493 shares of company stock valued at $9,475,510. Company insiders own 0.54% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

TEVA stock opened at $34.39 on Tuesday. The company has a quick ratio of 0.67, a current ratio of 0.88 and a debt-to-equity ratio of 1.56. Teva Pharmaceutical Industries Ltd. has a 12 month low of $15.46 and a 12 month high of $37.35. The firm has a market cap of $39.54 billion, a P/E ratio of 57.32, a P/E/G ratio of 3.70 and a beta of 0.86. The company’s 50-day moving average price is $33.24 and its two-hundred day moving average price is $32.75.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Tuesday, June 30th. The company reported $0.02 earnings per share for the quarter. The company had revenue of $4.14 billion during the quarter. Teva Pharmaceutical Industries had a net margin of 4.08% and a return on equity of 32.64%. On average, analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 1.98 earnings per share for the current fiscal year.

Analysts Set New Price Targets

TEVA has been the topic of a number of analyst reports. Truist Financial increased their target price on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Bank of America lifted their price target on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, April 9th. Wall Street Zen cut Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. UBS Group increased their price target on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Finally, Barclays raised their price objective on Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 6th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $42.00.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.